The dual glucose-dependent insulinotropic peptide and glucagon-like peptide-1 receptor agonist, tirzepatide, improves lipoprotein biomarkers associated with insulin resistance and cardiovascular risk in patients with type 2 diabetes.

Wilson JM, Nikooienejad A, Robins DA, Roell WC, Riesmeyer JS, Haupt A, Duffin KL, Taskinen MR, Ruotolo G

Diabetes, obesity & metabolism15 Sept 2020Cited by 123 (Europe PMC)

PMID33462955PMCIDPMC7756479DOI10.1111/dom.14174PepBankPUB-33462955

Read at source PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC-ND. Results still quote short attributed sentences.

Results from this study21

21 results from studies that gave the peptide. 21 results from people.

01HumanRandomized controlled trialEfficacy outcome
In patients with type 2 diabetes, tirzepatide decreased apoB levels in a dose-dependent way versus placebo at 26 weeks.
In plain wordsIn people with type 2 diabetes, tirzepatide lowered apoB, a blood fat marker, more than placebo, with larger doses giving larger falls.
Peptide
Tirzepatide
Outcome
DecreaseApoB level at 26 weeks
Study
n: not reported in source
Comparator
Placebo
Outcome group
Lipids · Metabolic and weight
Studied dose
1, 5, 10 or 15 mg once weekly · subcutaneous · 26 weeksAs given in this study (human).
Source sentences
Summary
At 26 weeks, tirzepatide dose-dependently decreased apoB and apoC-III levels, and increased serum preheparin LPL compared with placebo.
2 context sentences(design, population, supporting numbers)
Summary · context
Patients were randomized to receive once-weekly subcutaneous tirzepatide (1, 5, 10 or 15 mg), dulaglutide (1.5 mg) or placebo.
Summary · context
Serum lipoprotein profile, apolipoprotein (apo) A-I, B and C-III and preheparin lipoprotein lipase (LPL) were measured at baseline and at 4, 12 and 26 weeks.
Report a problemFND-3346295501
02HumanRandomized controlled trialEfficacy outcome
In patients with type 2 diabetes, tirzepatide decreased apoC-III levels in a dose-dependent way versus placebo at 26 weeks.
In plain wordsIn people with type 2 diabetes, tirzepatide lowered apoC-III, a blood fat marker, more than placebo, with larger doses giving larger falls.
Peptide
Tirzepatide
Outcome
DecreaseApoC-III level at 26 weeks
Study
n: not reported in source
Comparator
Placebo
Outcome group
Lipids · Metabolic and weight
Studied dose
1, 5, 10 or 15 mg once weekly · subcutaneous · 26 weeksAs given in this study (human).
Source sentences
Summary
At 26 weeks, tirzepatide dose-dependently decreased apoB and apoC-III levels, and increased serum preheparin LPL compared with placebo.
2 context sentences(design, population, supporting numbers)
Summary · context
Patients were randomized to receive once-weekly subcutaneous tirzepatide (1, 5, 10 or 15 mg), dulaglutide (1.5 mg) or placebo.
Summary · context
Serum lipoprotein profile, apolipoprotein (apo) A-I, B and C-III and preheparin lipoprotein lipase (LPL) were measured at baseline and at 4, 12 and 26 weeks.
Report a problemFND-3346295502
03HumanRandomized controlled trialEfficacy outcome
In patients with type 2 diabetes, tirzepatide increased serum preheparin LPL versus placebo at 26 weeks.
In plain wordsIn people with type 2 diabetes, tirzepatide raised an enzyme that clears blood fats (LPL) more than placebo.
Peptide
Tirzepatide
Outcome
IncreasePreheparin lipoprotein lipase (LPL) at 26 weeks
Study
n: not reported in source
Comparator
Placebo
Outcome group
Lipids · Metabolic and weight
Studied dose
1, 5, 10 or 15 mg once weekly · subcutaneous · 26 weeksAs given in this study (human).
Source sentences
Summary
At 26 weeks, tirzepatide dose-dependently decreased apoB and apoC-III levels, and increased serum preheparin LPL compared with placebo.
2 context sentences(design, population, supporting numbers)
Summary · context
Patients were randomized to receive once-weekly subcutaneous tirzepatide (1, 5, 10 or 15 mg), dulaglutide (1.5 mg) or placebo.
Summary · context
Serum lipoprotein profile, apolipoprotein (apo) A-I, B and C-III and preheparin lipoprotein lipase (LPL) were measured at baseline and at 4, 12 and 26 weeks.
Report a problemFND-3346295503
04HumanRandomized controlled trialEfficacy outcome
In patients with type 2 diabetes, tirzepatide 10 and 15 mg decreased large triglyceride-rich lipoprotein particles compared with both placebo and dulaglutide.
In plain wordsIn people with type 2 diabetes, tirzepatide 10 and 15 mg lowered large blood fat particles more than placebo and more than dulaglutide.
Peptide
Tirzepatide
Outcome
DecreaseLarge triglyceride-rich lipoprotein particles (TRLP)
Study
n: not reported in source
Comparator
Placebo and dulaglutide
Outcome group
Lipids · Metabolic and weight
Studied dose
10 and 15 mg once weekly · subcutaneous · 26 weeksAs given in this study (human).
Source sentences
Summary
Tirzepatide 10 and 15 mg decreased large triglyceride-rich lipoprotein particles (TRLP), small low-density lipoprotein particles (LDLP) and LPIR score compared with both placebo and dulaglutide.
2 context sentences(design, population, supporting numbers)
Summary · context
Patients were randomized to receive once-weekly subcutaneous tirzepatide (1, 5, 10 or 15 mg), dulaglutide (1.5 mg) or placebo.
Summary · context
Serum lipoprotein profile, apolipoprotein (apo) A-I, B and C-III and preheparin lipoprotein lipase (LPL) were measured at baseline and at 4, 12 and 26 weeks.
Report a problemFND-3346295504
05HumanRandomized controlled trialEfficacy outcome
In patients with type 2 diabetes, tirzepatide 10 and 15 mg decreased small LDL particles compared with both placebo and dulaglutide.
In plain wordsIn people with type 2 diabetes, tirzepatide 10 and 15 mg lowered small LDL particles more than placebo and more than dulaglutide.
Peptide
Tirzepatide
Outcome
DecreaseSmall low-density lipoprotein particles (LDLP)
Study
n: not reported in source
Comparator
Placebo and dulaglutide
Outcome group
Lipids · Metabolic and weight
Studied dose
10 and 15 mg once weekly · subcutaneous · 26 weeksAs given in this study (human).
Source sentences
Summary
Tirzepatide 10 and 15 mg decreased large triglyceride-rich lipoprotein particles (TRLP), small low-density lipoprotein particles (LDLP) and LPIR score compared with both placebo and dulaglutide.
2 context sentences(design, population, supporting numbers)
Summary · context
Patients were randomized to receive once-weekly subcutaneous tirzepatide (1, 5, 10 or 15 mg), dulaglutide (1.5 mg) or placebo.
Summary · context
Serum lipoprotein profile, apolipoprotein (apo) A-I, B and C-III and preheparin lipoprotein lipase (LPL) were measured at baseline and at 4, 12 and 26 weeks.
Report a problemFND-3346295505
06HumanRandomized controlled trialEfficacy outcome
In patients with type 2 diabetes, tirzepatide 10 and 15 mg decreased the LPIR score compared with both placebo and dulaglutide.
In plain wordsIn people with type 2 diabetes, tirzepatide 10 and 15 mg lowered a blood fat marker of insulin resistance more than placebo and dulaglutide.
Peptide
Tirzepatide
Outcome
DecreaseLipoprotein insulin resistance (LPIR) score
Study
n: not reported in source
Comparator
Placebo and dulaglutide
Outcome group
Lipids · Metabolic and weight
Studied dose
10 and 15 mg once weekly · subcutaneous · 26 weeksAs given in this study (human).
Source sentences
Summary
Tirzepatide 10 and 15 mg decreased large triglyceride-rich lipoprotein particles (TRLP), small low-density lipoprotein particles (LDLP) and LPIR score compared with both placebo and dulaglutide.
2 context sentences(design, population, supporting numbers)
Summary · context
Patients were randomized to receive once-weekly subcutaneous tirzepatide (1, 5, 10 or 15 mg), dulaglutide (1.5 mg) or placebo.
Summary · context
Serum lipoprotein profile, apolipoprotein (apo) A-I, B and C-III and preheparin lipoprotein lipase (LPL) were measured at baseline and at 4, 12 and 26 weeks.
Report a problemFND-3346295506
07HumanRandomized controlled trialEfficacy outcome
In patients with type 2 diabetes, tirzepatide 10 and 15 mg decreased the number of total LDL particles compared with placebo.
In plain wordsIn people with type 2 diabetes, tirzepatide 10 and 15 mg lowered the number of LDL particles more than placebo.
Peptide
Tirzepatide
Outcome
DecreaseTotal LDL particle number
Study
n: not reported in source
Comparator
Placebo
Outcome group
Lipids · Metabolic and weight
Studied dose
10 and 15 mg once weekly · subcutaneous · 26 weeksAs given in this study (human).
Source sentences
Summary
The number of total LDLP was also decreased with tirzepatide 10 and 15 mg compared with placebo.
2 context sentences(design, population, supporting numbers)
Summary · context
Patients were randomized to receive once-weekly subcutaneous tirzepatide (1, 5, 10 or 15 mg), dulaglutide (1.5 mg) or placebo.
Summary · context
Serum lipoprotein profile, apolipoprotein (apo) A-I, B and C-III and preheparin lipoprotein lipase (LPL) were measured at baseline and at 4, 12 and 26 weeks.
Report a problemFND-3346295507
08HumanRandomized controlled trialEfficacy outcome
In patients with type 2 diabetes, tirzepatide reduced apoC-III more in patients with high baseline triglycerides than in those with normal baseline triglycerides.
In plain wordsIn people with type 2 diabetes, tirzepatide lowered apoC-III more in those with high starting triglycerides than in those with normal ones.
Peptide
Tirzepatide
Outcome
DecreaseApoC-III reduction by baseline triglyceride level
Study
n: not reported in source
Comparator
Patients with normal baseline triglycerides
Outcome group
Lipids · Metabolic and weight
Studied dose
1, 5, 10 or 15 mg once weekly · subcutaneous · 26 weeksAs given in this study (human).
Source sentences
Summary
A greater reduction in apoC-III with tirzepatide was observed in patients with high compared with normal baseline triglycerides.
2 context sentences(design, population, supporting numbers)
Summary · context
Patients were randomized to receive once-weekly subcutaneous tirzepatide (1, 5, 10 or 15 mg), dulaglutide (1.5 mg) or placebo.
Summary · context
Serum lipoprotein profile, apolipoprotein (apo) A-I, B and C-III and preheparin lipoprotein lipase (LPL) were measured at baseline and at 4, 12 and 26 weeks.
Report a problemFND-3346295508
09HumanRandomized controlled trialMechanism
In patients with type 2 diabetes, change in apoC-III, but not body weight, was the best predictor of triglyceride change with tirzepatide at 26 weeks, explaining up to 22.9% of the variability.
In plain wordsIn people with type 2 diabetes, the change in apoC-III, not weight change, best predicted the fall in triglycerides with tirzepatide.
Peptide
Tirzepatide
Outcome
Not applicablePredictors of triglyceride change
Study
n: not reported in source
Outcome group
Lipids · Metabolic and weight
Studied dose
1, 5, 10 or 15 mg once weekly · subcutaneous · 26 weeksAs given in this study (human).
Measurements
Variability in triglyceride change explained by apoC-III change
≤ 22.9%
tirzepatide
Source sentences
Summary
At 26 weeks, change in apoC-III, but not body weight, was the best predictor of changes in triglycerides with tirzepatide, explaining up to 22.9% of their variability.
2 context sentences(design, population, supporting numbers)
Summary · context
Patients were randomized to receive once-weekly subcutaneous tirzepatide (1, 5, 10 or 15 mg), dulaglutide (1.5 mg) or placebo.
Summary · context
Serum lipoprotein profile, apolipoprotein (apo) A-I, B and C-III and preheparin lipoprotein lipase (LPL) were measured at baseline and at 4, 12 and 26 weeks.
Report a problemFND-3346295509
10HumanRandomized controlled trialEfficacy outcome
In patients with type 2 diabetes, dulaglutide reduced apoB levels.
In plain wordsIn patients with diabetes, dulaglutide reduced apoB levels.
Peptide
Dulaglutide (Trulicity)
Outcome
DecreaseApoB
Study
n: not reported in source
Outcome group
Lipids · Metabolic and weight
Studied dose
1.5 mg weekly · subcutaneous · 26 weeksAs given in this study (human).
Source sentences
Summary
Treatment with dulaglutide also reduced apoB and apoC-III levels but had no effect on either serum LPL or large TRLP, small LDLP and LPIR score.
2 context sentences(design, population, supporting numbers)
Summary · context
Patients were randomized to receive once-weekly subcutaneous tirzepatide (1, 5, 10 or 15 mg), dulaglutide (1.5 mg) or placebo.
Summary · context
Serum lipoprotein profile, apolipoprotein (apo) A-I, B and C-III and preheparin lipoprotein lipase (LPL) were measured at baseline and at 4, 12 and 26 weeks.
Report a problemFND-3346295510
11HumanRandomized controlled trialEfficacy outcome
In patients with type 2 diabetes, dulaglutide reduced apoC-III levels.
In plain wordsIn patients with diabetes, dulaglutide reduced apoC-III levels.
Peptide
Dulaglutide (Trulicity)
Outcome
DecreaseApoC-III
Study
n: not reported in source
Outcome group
Lipids · Metabolic and weight
Studied dose
1.5 mg weekly · subcutaneous · 26 weeksAs given in this study (human).
Source sentences
Summary
Treatment with dulaglutide also reduced apoB and apoC-III levels but had no effect on either serum LPL or large TRLP, small LDLP and LPIR score.
2 context sentences(design, population, supporting numbers)
Summary · context
Patients were randomized to receive once-weekly subcutaneous tirzepatide (1, 5, 10 or 15 mg), dulaglutide (1.5 mg) or placebo.
Summary · context
Serum lipoprotein profile, apolipoprotein (apo) A-I, B and C-III and preheparin lipoprotein lipase (LPL) were measured at baseline and at 4, 12 and 26 weeks.
Report a problemFND-3346295511
12HumanRandomized controlled trialEfficacy outcome
In patients with type 2 diabetes, dulaglutide had no effect on serum LPL.
In plain wordsIn patients with diabetes, dulaglutide had no effect on serum LPL.
Peptide
Dulaglutide (Trulicity)
Outcome
No significant changePreheparin LPL
Study
n: not reported in source
Outcome group
Lipids · Metabolic and weight
Studied dose
1.5 mg weekly · subcutaneous · 26 weeksAs given in this study (human).
Source sentences
Summary
Treatment with dulaglutide also reduced apoB and apoC-III levels but had no effect on either serum LPL or large TRLP, small LDLP and LPIR score.
2 context sentences(design, population, supporting numbers)
Summary · context
Patients were randomized to receive once-weekly subcutaneous tirzepatide (1, 5, 10 or 15 mg), dulaglutide (1.5 mg) or placebo.
Summary · context
Serum lipoprotein profile, apolipoprotein (apo) A-I, B and C-III and preheparin lipoprotein lipase (LPL) were measured at baseline and at 4, 12 and 26 weeks.
Report a problemFND-3346295512
13HumanRandomized controlled trialEfficacy outcome
In patients with type 2 diabetes, dulaglutide had no effect on large triglyceride-rich lipoprotein particles.
In plain wordsIn patients with diabetes, dulaglutide had no effect on large triglyceride-rich lipoprotein particles.
Peptide
Dulaglutide (Trulicity)
Outcome
No significant changeLarge TRLP
Study
n: not reported in source
Outcome group
Lipids · Metabolic and weight
Studied dose
1.5 mg weekly · subcutaneous · 26 weeksAs given in this study (human).
Source sentences
Summary
Treatment with dulaglutide also reduced apoB and apoC-III levels but had no effect on either serum LPL or large TRLP, small LDLP and LPIR score.
2 context sentences(design, population, supporting numbers)
Summary · context
Patients were randomized to receive once-weekly subcutaneous tirzepatide (1, 5, 10 or 15 mg), dulaglutide (1.5 mg) or placebo.
Summary · context
Serum lipoprotein profile, apolipoprotein (apo) A-I, B and C-III and preheparin lipoprotein lipase (LPL) were measured at baseline and at 4, 12 and 26 weeks.
Report a problemFND-3346295513
14HumanRandomized controlled trialEfficacy outcome
In patients with type 2 diabetes, dulaglutide had no effect on small LDL particles.
In plain wordsIn patients with diabetes, dulaglutide had no effect on small LDL particles.
Peptide
Dulaglutide (Trulicity)
Outcome
No significant changeSmall LDLP
Study
n: not reported in source
Outcome group
Lipids · Metabolic and weight
Studied dose
1.5 mg weekly · subcutaneous · 26 weeksAs given in this study (human).
Source sentences
Summary
Treatment with dulaglutide also reduced apoB and apoC-III levels but had no effect on either serum LPL or large TRLP, small LDLP and LPIR score.
2 context sentences(design, population, supporting numbers)
Summary · context
Patients were randomized to receive once-weekly subcutaneous tirzepatide (1, 5, 10 or 15 mg), dulaglutide (1.5 mg) or placebo.
Summary · context
Serum lipoprotein profile, apolipoprotein (apo) A-I, B and C-III and preheparin lipoprotein lipase (LPL) were measured at baseline and at 4, 12 and 26 weeks.
Report a problemFND-3346295514
15HumanRandomized controlled trialEfficacy outcome
In patients with type 2 diabetes, dulaglutide had no effect on the lipoprotein insulin resistance score.
In plain wordsIn patients with diabetes, dulaglutide had no effect on the lipoprotein insulin resistance score.
Peptide
Dulaglutide (Trulicity)
Outcome
No significant changeLPIR score
Study
n: not reported in source
Outcome group
Glycemic control · Metabolic and weight
Studied dose
1.5 mg weekly · subcutaneous · 26 weeksAs given in this study (human).
Source sentences
Summary
Treatment with dulaglutide also reduced apoB and apoC-III levels but had no effect on either serum LPL or large TRLP, small LDLP and LPIR score.
2 context sentences(design, population, supporting numbers)
Summary · context
Patients were randomized to receive once-weekly subcutaneous tirzepatide (1, 5, 10 or 15 mg), dulaglutide (1.5 mg) or placebo.
Summary · context
Serum lipoprotein profile, apolipoprotein (apo) A-I, B and C-III and preheparin lipoprotein lipase (LPL) were measured at baseline and at 4, 12 and 26 weeks.
Report a problemFND-3346295515
16HumanRandomized controlled trialEfficacy outcome
In patients with diabetes, dulaglutide produced higher large TRLP levels than tirzepatide 10 mg.
In plain wordsIn patients with diabetes, dulaglutide produced higher large TRLP levels than tirzepatide 10 mg.
Peptide
Dulaglutide (Trulicity)
Outcome
IncreaseLarge TRLP versus tirzepatide 10 mg
Study
n: not reported in source
Comparator
Tirzepatide 10 mg
Outcome group
Lipids · Metabolic and weight
Studied dose
1.5 mg weekly · subcutaneous · 26 weeksAs given in this study (human).
Source sentences
Summary
Tirzepatide 10 and 15 mg decreased large triglyceride-rich lipoprotein particles (TRLP), small low-density lipoprotein particles (LDLP) and LPIR score compared with both placebo and dulaglutide.
2 context sentences(design, population, supporting numbers)
Summary · context
Patients were randomized to receive once-weekly subcutaneous tirzepatide (1, 5, 10 or 15 mg), dulaglutide (1.5 mg) or placebo.
Summary · context
Serum lipoprotein profile, apolipoprotein (apo) A-I, B and C-III and preheparin lipoprotein lipase (LPL) were measured at baseline and at 4, 12 and 26 weeks.
Report a problemFND-3346295516
17HumanRandomized controlled trialEfficacy outcome
In patients with diabetes, dulaglutide produced higher large TRLP levels than tirzepatide 15 mg.
In plain wordsIn patients with diabetes, dulaglutide produced higher large TRLP levels than tirzepatide 15 mg.
Peptide
Dulaglutide (Trulicity)
Outcome
IncreaseLarge TRLP versus tirzepatide 15 mg
Study
n: not reported in source
Comparator
Tirzepatide 15 mg
Outcome group
Lipids · Metabolic and weight
Studied dose
1.5 mg weekly · subcutaneous · 26 weeksAs given in this study (human).
Source sentences
Summary
Tirzepatide 10 and 15 mg decreased large triglyceride-rich lipoprotein particles (TRLP), small low-density lipoprotein particles (LDLP) and LPIR score compared with both placebo and dulaglutide.
2 context sentences(design, population, supporting numbers)
Summary · context
Patients were randomized to receive once-weekly subcutaneous tirzepatide (1, 5, 10 or 15 mg), dulaglutide (1.5 mg) or placebo.
Summary · context
Serum lipoprotein profile, apolipoprotein (apo) A-I, B and C-III and preheparin lipoprotein lipase (LPL) were measured at baseline and at 4, 12 and 26 weeks.
Report a problemFND-3346295517
18HumanRandomized controlled trialEfficacy outcome
In patients with diabetes, dulaglutide produced higher small LDLP levels than tirzepatide 10 mg.
In plain wordsIn patients with diabetes, dulaglutide produced higher small LDLP levels than tirzepatide 10 mg.
Peptide
Dulaglutide (Trulicity)
Outcome
IncreaseSmall LDLP versus tirzepatide 10 mg
Study
n: not reported in source
Comparator
Tirzepatide 10 mg
Outcome group
Lipids · Metabolic and weight
Studied dose
1.5 mg weekly · subcutaneous · 26 weeksAs given in this study (human).
Source sentences
Summary
Tirzepatide 10 and 15 mg decreased large triglyceride-rich lipoprotein particles (TRLP), small low-density lipoprotein particles (LDLP) and LPIR score compared with both placebo and dulaglutide.
2 context sentences(design, population, supporting numbers)
Summary · context
Patients were randomized to receive once-weekly subcutaneous tirzepatide (1, 5, 10 or 15 mg), dulaglutide (1.5 mg) or placebo.
Summary · context
Serum lipoprotein profile, apolipoprotein (apo) A-I, B and C-III and preheparin lipoprotein lipase (LPL) were measured at baseline and at 4, 12 and 26 weeks.
Report a problemFND-3346295518
19HumanRandomized controlled trialEfficacy outcome
In patients with diabetes, dulaglutide produced higher small LDLP levels than tirzepatide 15 mg.
In plain wordsIn patients with diabetes, dulaglutide produced higher small LDLP levels than tirzepatide 15 mg.
Peptide
Dulaglutide (Trulicity)
Outcome
IncreaseSmall LDLP versus tirzepatide 15 mg
Study
n: not reported in source
Comparator
Tirzepatide 15 mg
Outcome group
Lipids · Metabolic and weight
Studied dose
1.5 mg weekly · subcutaneous · 26 weeksAs given in this study (human).
Source sentences
Summary
Tirzepatide 10 and 15 mg decreased large triglyceride-rich lipoprotein particles (TRLP), small low-density lipoprotein particles (LDLP) and LPIR score compared with both placebo and dulaglutide.
2 context sentences(design, population, supporting numbers)
Summary · context
Patients were randomized to receive once-weekly subcutaneous tirzepatide (1, 5, 10 or 15 mg), dulaglutide (1.5 mg) or placebo.
Summary · context
Serum lipoprotein profile, apolipoprotein (apo) A-I, B and C-III and preheparin lipoprotein lipase (LPL) were measured at baseline and at 4, 12 and 26 weeks.
Report a problemFND-3346295519
20HumanRandomized controlled trialEfficacy outcome
In patients with diabetes, dulaglutide produced higher LPIR scores than tirzepatide 10 mg.
In plain wordsIn patients with diabetes, dulaglutide produced higher insulin resistance scores than tirzepatide 10 mg.
Peptide
Dulaglutide (Trulicity)
Outcome
IncreaseLPIR versus tirzepatide 10 mg
Study
n: not reported in source
Comparator
Tirzepatide 10 mg
Outcome group
Glycemic control · Metabolic and weight
Studied dose
1.5 mg weekly · subcutaneous · 26 weeksAs given in this study (human).
Source sentences
Summary
Tirzepatide 10 and 15 mg decreased large triglyceride-rich lipoprotein particles (TRLP), small low-density lipoprotein particles (LDLP) and LPIR score compared with both placebo and dulaglutide.
2 context sentences(design, population, supporting numbers)
Summary · context
Patients were randomized to receive once-weekly subcutaneous tirzepatide (1, 5, 10 or 15 mg), dulaglutide (1.5 mg) or placebo.
Summary · context
Serum lipoprotein profile, apolipoprotein (apo) A-I, B and C-III and preheparin lipoprotein lipase (LPL) were measured at baseline and at 4, 12 and 26 weeks.
Report a problemFND-3346295520
21HumanRandomized controlled trialEfficacy outcome
In patients with type 2 diabetes, LPIR score was lower with tirzepatide 15 mg than with dulaglutide, and dulaglutide had no effect on LPIR score.
In plain wordsIn patients with type 2 diabetes, lipoprotein insulin resistance scores were lower with tirzepatide 15 mg than with dulaglutide, which had no effect.
Peptide
Dulaglutide (Trulicity)
Outcome
IncreaseLPIR versus tirzepatide 15 mg
Study
n: not reported in source
Comparator
Tirzepatide 15 mg
Outcome group
Lipids · Metabolic and weight
Studied dose
1.5 mg weekly · subcutaneous · 26 weeksAs given in this study (human).
Source sentences
Summary
Tirzepatide 10 and 15 mg decreased large triglyceride-rich lipoprotein particles (TRLP), small low-density lipoprotein particles (LDLP) and LPIR score compared with both placebo and dulaglutide.
2 context sentences(design, population, supporting numbers)
Summary · context
Patients were randomized to receive once-weekly subcutaneous tirzepatide (1, 5, 10 or 15 mg), dulaglutide (1.5 mg) or placebo.
Summary · context
Serum lipoprotein profile, apolipoprotein (apo) A-I, B and C-III and preheparin lipoprotein lipase (LPL) were measured at baseline and at 4, 12 and 26 weeks.
Report a problemFND-3346295521

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Versions 4 to 8Current
28 Oct 2026, 02:03 UTC
The same notice was added 5 times, first on 22 Oct 2026, 02:26 UTC. The status did not change between them.
Study results updated
Version 3
21 Oct 2026, 18:59 UTC
Study data updated · source update from Europe PMC
Version 2
12 Oct 2026, 12:58 UTC
Study results updated
Version 1
9 Oct 2026, 03:07 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

Keywords

Incretin Therapy, Type 2 Diabetes

PepBank is a research reference. Talk to a doctor before you use any peptide.